Latest News

  • Ageing must become central to Parkinson’s research, experts say

    Ageing should be central to Parkinson’s research, experts argue, saying it has been sidelined as studies focused on genetics and single disease mechanisms. Parkinson’s is a progressive neurological condition that affects movement and can cause tremors, stiffness and balance problems. It affects about one million people in the US and more than ten million worldwide, [...]

  • Return to traditional lentil and rice diet could help curb diabetes in Nepal

    Traditional dal bhat could help curb Nepal’s diabetes crisis, with one in five people over 40 living with type 2 diabetes, researchers say. With medication often unaffordable, researchers are testing whether cheap, local staples such as lentils and rice can help tackle type 2 diabetes, where blood sugar stays high because the body does not [...]

  • Brain training reduces dementia risk, study finds

    Processing-speed brain training with booster sessions was linked to a lower dementia diagnosis risk over 20 years, according to a long follow-up study. The findings come from extended tracking of a large randomised controlled trial, where participants were assigned by chance to different training programmes or no intervention. Researchers linked trial records to US Medicare [...]

  • Agetech investment & innovation round-up

    Long-term gut health and female finance, London likes longevity New York innovator Salvo Health has secured $8.5m in Series A round as it looks to develop new, long-term, gut-health treatments. The funding round was led by ManchesterStory, City Light Capital and Threshold Ventures, with additional support from The Artemis Fund, Owl Capital, Impact X Capital [...]

  • Bryan Johnson launches US$1m longevity programme

    Bryan Johnson has launched a US$1m-a-year longevity programme with just three places, offering access to the exact protocol he has followed for five years. The programme, called "Immortals", is offered by the former fintech entrepreneur, now a prominent and often controversial figure in longevity. Johnson’s unconventional methods have included Botox injections in his genitals (Botox [...]

  • Re:Cognition and Cera expand Alzheimer’s clinical trials access

    Re:Cognition Health and Cera have partnered to expand access to Alzheimer’s clinical trials across the UK. The collaboration links Re:Cognition Health’s specialist brain health clinics and trial expertise with Cera’s 2.5 million monthly home care visits, creating new pathways to identify and support people earlier in their health journey. By connecting home care with specialist [...]

  • First blood test for Alzheimer’s in primary care

    Labcorp has launched what it describes as the first FDA-cleared blood test for Alzheimer's disease assessment in primary care settings nationwide. The Elecsys pTau-181 helps clinicians rule out the neurodegenerative disorder by identifying which symptomatic patients aged 55 and older are unlikely to have amyloid pathology, abnormal protein build-up in the brain associated with the [...]

  • Space station partnership for bioprinting research

    Starlab Space has announced a partnership with Auxilium Biotechnologies to advance 3D bioprinting in orbit. Auxilium will provide orbital 3D bioprinting and biofabrication capabilities (manufacturing biological materials) aboard the Starlab space station to support research and development in regenerative medicine, implantable medical devices and tissue engineering. Regenerative medicine uses the body’s own materials to repair [...]

  • Dubai Healthcare City expands longevity offering

    Dubai Healthcare City has expanded its longevity and pharmaceutical services at the World Health Expo Dubai 2026. The expansion brings together what the free zone describes as a new longevity-led preventive care programme and an AI-driven tele-compounding pharmacy platform. The additions expand the range of personalised care pathways available within the ecosystem, with a focus [...]

  • French biotech raises €12m for osteoarthritis trial

    A French biotech has raised €12m to test whether GLP-1 drugs can modify osteoarthritis progression. The funding will advance 4Moving Biotech's lead programme, 4P004, toward a phase 2a proof-of-concept readout in knee osteoarthritis, a joint disease that causes pain and stiffness. Despite affecting more than 600 million people worldwide, no therapy approved in Europe or [...]